Siemens Healthineers Showcases Atellica Solution at AACC 2017
|
By LabMedica International staff writers Posted on 07 Aug 2017 |

Image: The Atellica Solution (Photo courtesy of Siemens Healthineers).
Siemens Healthineers (Erlangen, Germany), the separately managed healthcare business of Siemens AG, showcased the Atellica Solution – flexible, scalable, automation-ready immunoassay and chemistry analyzers for laboratory diagnostics – at the 69th AACC Annual Scientific Meeting & Clinical Lab Expo, the world’s largest exposition for clinical laboratory products and services.
Siemens Healthineers offers a comprehensive portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. The company was among over 750 exhibitors who displayed pioneering diagnostic technology, including the latest in mobile health, molecular diagnostics, mass spectrometry, point-of-care (POC), and automation at the 2017 AACC Clinical Lab Expo held at the San Diego Convention Center from August 1-3.
The recently 510(k)-cleared Atellica Solution is comprised of sample management and immunoassay and chemistry analyzer components. It can combine up to 10 components into more than 300 customizable configurations – including linear, L and U shapes. With an immunoassay analyzer that runs up to 440 tests per hour, the Atellica Solution is suitable for mid-and high-volume labs. The product was displayed as a stand-alone system at AACC 2017 and connected to Aptio Automation to demonstrate a comprehensive multi-disciplinary solution.
“Siemens Healthineers is driving healthcare forward in the digital age by delivering fast and easy interaction between data and knowledge, to go along with our complete in vivo and in vitro offerings,” said Michael Reitermann, Chief Operating Officer, Siemens Healthineers.
Siemens Healthineers also exhibited the Atellica Diagnostics IT family of products, which includes connectivity management, data management, inventory management, process management and clinical decision support for multi-site laboratories seeking real-time analytics to improve workflow and efficiency. Atellica Diagnostics IT features customizable parameters, performance-monitoring capabilities, and centralized control over the day-to-day laboratory operations to improve business and clinical outcomes.
“FDA clearance for the Atellica Solution opens the door for us to change the game in laboratory diagnostics with a revolutionary platform designed by customers for customers,” said Franz Walt, President, Laboratory Diagnostics, Siemens Healthineers. “Combined with the Atellica Solution, our highly integrated Atellica Diagnostics IT will simplify lab workflows to meet increasing testing demand.”
The company also showcased its complete POC informatics portfolio with offerings for secure connectivity to more than 160 devices from over 40 vendors. The solutions are designed to streamline operations and centrally manage all POCT devices.
“Open connectivity, regardless of the manufacturer, for point-of-care instruments addresses key pain points that previously challenged the implementation of point-of-care testing,” said Peter Koerte, President, Point of Care Diagnostics, Siemens Healthineers. “Further, the latest advances in connectivity provide POC coordinators valuable data for better decision-making to support improved patient outcomes.”
Siemens Healthineers’ informatics offerings include RAPIDComm Data Management System for managing and controlling POC testing programs, POCcelerator Software, which connects POCT devices from all manufacturers to a hospital’s IT system, and UniPOC Software, which seamlessly connects and manages POC devices from numerous manufacturers through a single enterprise platform for laboratories that prefer a vendor-independent approach.
Additionally, Siemens Healthineers celebrated the US launch of Xprecia Stride, a handheld portable coagulation analyzer for Prothrombin Time International Normalized Ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist.
Siemens Healthineers offers a comprehensive portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. The company was among over 750 exhibitors who displayed pioneering diagnostic technology, including the latest in mobile health, molecular diagnostics, mass spectrometry, point-of-care (POC), and automation at the 2017 AACC Clinical Lab Expo held at the San Diego Convention Center from August 1-3.
The recently 510(k)-cleared Atellica Solution is comprised of sample management and immunoassay and chemistry analyzer components. It can combine up to 10 components into more than 300 customizable configurations – including linear, L and U shapes. With an immunoassay analyzer that runs up to 440 tests per hour, the Atellica Solution is suitable for mid-and high-volume labs. The product was displayed as a stand-alone system at AACC 2017 and connected to Aptio Automation to demonstrate a comprehensive multi-disciplinary solution.
“Siemens Healthineers is driving healthcare forward in the digital age by delivering fast and easy interaction between data and knowledge, to go along with our complete in vivo and in vitro offerings,” said Michael Reitermann, Chief Operating Officer, Siemens Healthineers.
Siemens Healthineers also exhibited the Atellica Diagnostics IT family of products, which includes connectivity management, data management, inventory management, process management and clinical decision support for multi-site laboratories seeking real-time analytics to improve workflow and efficiency. Atellica Diagnostics IT features customizable parameters, performance-monitoring capabilities, and centralized control over the day-to-day laboratory operations to improve business and clinical outcomes.
“FDA clearance for the Atellica Solution opens the door for us to change the game in laboratory diagnostics with a revolutionary platform designed by customers for customers,” said Franz Walt, President, Laboratory Diagnostics, Siemens Healthineers. “Combined with the Atellica Solution, our highly integrated Atellica Diagnostics IT will simplify lab workflows to meet increasing testing demand.”
The company also showcased its complete POC informatics portfolio with offerings for secure connectivity to more than 160 devices from over 40 vendors. The solutions are designed to streamline operations and centrally manage all POCT devices.
“Open connectivity, regardless of the manufacturer, for point-of-care instruments addresses key pain points that previously challenged the implementation of point-of-care testing,” said Peter Koerte, President, Point of Care Diagnostics, Siemens Healthineers. “Further, the latest advances in connectivity provide POC coordinators valuable data for better decision-making to support improved patient outcomes.”
Siemens Healthineers’ informatics offerings include RAPIDComm Data Management System for managing and controlling POC testing programs, POCcelerator Software, which connects POCT devices from all manufacturers to a hospital’s IT system, and UniPOC Software, which seamlessly connects and manages POC devices from numerous manufacturers through a single enterprise platform for laboratories that prefer a vendor-independent approach.
Additionally, Siemens Healthineers celebrated the US launch of Xprecia Stride, a handheld portable coagulation analyzer for Prothrombin Time International Normalized Ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist.
Latest AACC 2017 News
- Ortho Clinical Diagnostics Highlights Immunodiagnostics at Clinical Expo
- Combating Infectious Diseases Key Focus of AACC
- World's First Fully Integrated LC-MS/MS Clinical Analyzer Unveiled
- Clinical Chemistry Analyzer Provides DAU Screening
- Diatron Displays New Hematology Analyzer at UAE Congress
- Microscan Demonstrates Advanced Technology at Scientific Meeting
- AACC Middle East to Be Held in Abu Dhabi
- AACC 2017 Focus on CRISPR and Futuristic Testing Devices
- Opioid Drug Abuse Testing Key Topic at Congress
- Keynote Address to Focus on CRISPR/Cas9 Gene Editing
- Winner of Qualcomm Tricorder XPrize Unveiled at AACC
- Annual Meeting Offers Industry Education and Entertainment
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








